EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19
EPI CV COVID
1 other identifier
observational
35
1 country
1
Brief Summary
The COVID-19 pandemic highlights the importance of the prognosis of co-morbidities, such as coronary artery disease, which significantly increase the risk of mortality in patients infected with SARS-CoV2. Investigators have recently studied the complex links between respiratory infections, particularly pneumonia, and type 2 myocardial infarction (MI) in many respects. The etiology of type 2 MI is based on an imbalance of myocardial oxygen supply/need in the absence of rupture/erosion of atheromatous plaques. Based on the RICO survey data, the investigators investigated whether COVID-19-related sepsis and/or respiratory failure could be an underlying mechanism of MI2.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 15, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2020
CompletedFirst Submitted
Initial submission to the registry
August 3, 2020
CompletedFirst Posted
Study publicly available on registry
August 4, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2021
CompletedAugust 4, 2020
August 1, 2020
4 months
August 3, 2020
August 3, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Characterizing type 2 myocardial infarction associated with CoV-2 SARS infection
Through study completion, an average of 1 year
Study Arms (4)
A
Type 2 MI with COVID-19
B
Type 2 without COVID-19
C
Type 2 MI with pneumonia without COVID-19
D
Type 2 MI without pneumonia and without COVID-19
Interventions
Eligibility Criteria
patients with acute type 2 MI
You may qualify if:
- patients hospitalized for a type 2 MI in CCU from CHU Dijon Bourgogne With or without pneumonia
- patients hospitalized for a type 2 MI in CCU from CHU Dijon Bourgogne With or without COVID 19
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chu Dijon Bourgogne
Dijon, 21000, France
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 3, 2020
First Posted
August 4, 2020
Study Start
March 15, 2020
Primary Completion
July 1, 2020
Study Completion
July 1, 2021
Last Updated
August 4, 2020
Record last verified: 2020-08